Trexquant Investment LP Has $778,000 Stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Trexquant Investment LP grew its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRXGet Rating) by 22.2% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 73,512 shares of the biotechnology company’s stock after buying an additional 13,359 shares during the period. Trexquant Investment LP’s holdings in BioCryst Pharmaceuticals were worth $778,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in BCRX. Diversified Trust Co increased its stake in shares of BioCryst Pharmaceuticals by 6.6% during the second quarter. Diversified Trust Co now owns 19,408 shares of the biotechnology company’s stock worth $205,000 after purchasing an additional 1,200 shares during the period. Semmax Financial Advisors Inc. increased its stake in shares of BioCryst Pharmaceuticals by 389.6% during the first quarter. Semmax Financial Advisors Inc. now owns 1,699 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 1,352 shares during the period. Arizona State Retirement System increased its stake in shares of BioCryst Pharmaceuticals by 2.9% during the second quarter. Arizona State Retirement System now owns 50,043 shares of the biotechnology company’s stock worth $529,000 after purchasing an additional 1,403 shares during the period. E Fund Management Co. Ltd. increased its stake in shares of BioCryst Pharmaceuticals by 11.8% during the first quarter. E Fund Management Co. Ltd. now owns 16,641 shares of the biotechnology company’s stock worth $271,000 after purchasing an additional 1,756 shares during the period. Finally, Fairfield Bush & CO. bought a new position in shares of BioCryst Pharmaceuticals during the first quarter worth approximately $34,000. 80.68% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

BCRX has been the topic of a number of recent research reports. Royal Bank of Canada lowered their target price on BioCryst Pharmaceuticals from $14.00 to $13.00 and set a “sector perform” rating on the stock in a research note on Wednesday, November 2nd. Barclays raised their price objective on BioCryst Pharmaceuticals from $12.00 to $14.00 and gave the stock an “equal weight” rating in a research note on Friday, August 5th. StockNews.com assumed coverage on BioCryst Pharmaceuticals in a research note on Wednesday, October 12th. They issued a “hold” rating on the stock. Evercore ISI upgraded BioCryst Pharmaceuticals from an “in-line” rating to an “outperform” rating and lifted their price target for the company from $14.00 to $16.00 in a research note on Wednesday, November 2nd. Finally, Oppenheimer lowered BioCryst Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Friday, August 5th. Six analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $17.00.

Insider Activity at BioCryst Pharmaceuticals

In related news, insider Yarlagadda S. Babu sold 31,515 shares of the firm’s stock in a transaction on Monday, November 14th. The stock was sold at an average price of $13.88, for a total transaction of $437,428.20. Following the sale, the insider now owns 298,541 shares of the company’s stock, valued at approximately $4,143,749.08. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 5.00% of the stock is currently owned by company insiders.

BioCryst Pharmaceuticals Stock Down 2.4 %

NASDAQ BCRX opened at $12.39 on Friday. BioCryst Pharmaceuticals, Inc. has a twelve month low of $7.61 and a twelve month high of $19.99. The company has a market cap of $2.31 billion, a price-to-earnings ratio of -11.80 and a beta of 2.00. The business’s fifty day moving average is $13.08 and its 200 day moving average is $12.03.

BioCryst Pharmaceuticals Company Profile

(Get Rating)

BioCryst Pharmaceuticals, Inc, a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.

Featured Stories

Want to see what other hedge funds are holding BCRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRXGet Rating).

Institutional Ownership by Quarter for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.